Weekly Digest – February 2026 Weekly Digest – February 2026 30 January 2026: Astellas submits Supplemental New Drug Application in Japan for PADCEV™ (Enfortumab vedotin) with Keytruda ® (Pembrolizumab) for certain patients with muscle-invasive bladder cancer Astellas Pharma has advanced […]